CY1111467T1 - Μορια ανθρωπινου αντισωματος για την il-13 - Google Patents
Μορια ανθρωπινου αντισωματος για την il-13Info
- Publication number
- CY1111467T1 CY1111467T1 CY20111100456T CY111100456T CY1111467T1 CY 1111467 T1 CY1111467 T1 CY 1111467T1 CY 20111100456 T CY20111100456 T CY 20111100456T CY 111100456 T CY111100456 T CY 111100456T CY 1111467 T1 CY1111467 T1 CY 1111467T1
- Authority
- CY
- Cyprus
- Prior art keywords
- motorcycle
- ill
- human response
- antibody molecules
- hodgkin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48751203P | 2003-07-15 | 2003-07-15 | |
| US55821604P | 2004-03-31 | 2004-03-31 | |
| GBGB0407315.1A GB0407315D0 (en) | 2003-07-15 | 2004-03-31 | Human antibody molecules |
| US57379104P | 2004-05-24 | 2004-05-24 | |
| EP04743400A EP1646656B1 (en) | 2003-07-15 | 2004-07-15 | Human antibody molecules for il-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111467T1 true CY1111467T1 (el) | 2015-08-05 |
Family
ID=44535047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100456T CY1111467T1 (el) | 2003-07-15 | 2011-05-16 | Μορια ανθρωπινου αντισωματος για την il-13 |
Country Status (8)
| Country | Link |
|---|---|
| JP (3) | JP5519567B2 (ja) |
| KR (1) | KR101073590B1 (ja) |
| AU (1) | AU2011200308B2 (ja) |
| CY (1) | CY1111467T1 (ja) |
| HK (3) | HK1097853A1 (ja) |
| MX (1) | MXPA06000258A (ja) |
| NO (2) | NO338853B1 (ja) |
| RU (1) | RU2009148270A (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952241A1 (en) * | 2014-06-18 | 2015-12-23 | Medimmune, Llc | Cell culture methods and media comprising n-acetylcysteine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5010793A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Human interleukin-13 |
| US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| JP2005512522A (ja) * | 2001-10-26 | 2005-05-12 | セントカー・インコーポレーテツド | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
| AU2002359568B2 (en) * | 2001-12-03 | 2008-02-21 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| AU2003260748A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2004
- 2004-07-15 KR KR1020067000933A patent/KR101073590B1/ko active IP Right Grant
- 2004-07-15 MX MXPA06000258A patent/MXPA06000258A/es active IP Right Grant
-
2006
- 2006-02-15 NO NO20060730A patent/NO338853B1/no unknown
-
2007
- 2007-02-15 HK HK07101860.8A patent/HK1097853A1/xx unknown
-
2009
- 2009-12-24 RU RU2009148270/10A patent/RU2009148270A/ru not_active Application Discontinuation
-
2011
- 2011-01-25 AU AU2011200308A patent/AU2011200308B2/en active Active
- 2011-04-07 JP JP2011085689A patent/JP5519567B2/ja active Active
- 2011-05-16 CY CY20111100456T patent/CY1111467T1/el unknown
- 2011-09-07 HK HK11109456.5A patent/HK1155185A1/zh unknown
-
2014
- 2014-02-05 JP JP2014020292A patent/JP5922686B2/ja active Active
-
2015
- 2015-12-08 JP JP2015239450A patent/JP2016047843A/ja active Pending
-
2016
- 2016-04-19 HK HK16104446.4A patent/HK1216427A1/zh unknown
- 2016-04-27 NO NO20160707A patent/NO342727B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009148270A (ru) | 2011-06-27 |
| JP5519567B2 (ja) | 2014-06-11 |
| MXPA06000258A (es) | 2006-07-03 |
| JP2014101372A (ja) | 2014-06-05 |
| NO338853B1 (no) | 2016-10-24 |
| HK1097853A1 (en) | 2007-07-06 |
| KR101073590B1 (ko) | 2011-10-14 |
| AU2011200308B2 (en) | 2011-07-28 |
| KR20060054312A (ko) | 2006-05-22 |
| NO20160707A1 (no) | 2016-04-27 |
| HK1216427A1 (zh) | 2016-11-11 |
| AU2011200308A1 (en) | 2011-02-17 |
| JP2011147454A (ja) | 2011-08-04 |
| JP5922686B2 (ja) | 2016-05-24 |
| HK1155185A1 (zh) | 2012-05-11 |
| JP2016047843A (ja) | 2016-04-07 |
| NO20060730L (no) | 2006-04-10 |
| NO342727B1 (no) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY144906A (en) | Human antibodies against il13 and therapeutic uses | |
| WO2005007699A8 (en) | Human antibody molecules for il-13 | |
| CY1120874T1 (el) | Συνθεση αντισωματος ιντερλευκινης-13 | |
| CY1120033T1 (el) | Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους | |
| TNSN08333A1 (en) | Thymic stromal lymphopoietin (tslp) antibodies and uses thereof | |
| NO20054223L (no) | Antistoffmolekyler som har spesifisitet for human IL-1beta | |
| BRPI0518241A (pt) | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade | |
| MX2009010765A (es) | Anticuerpos anti-ige. | |
| ATE407927T1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| Haider et al. | Decreased hippocampal 5-HT and DA levels following sub-chronic exposure to noise stress: impairment in both spatial and recognition memory in male rats | |
| DK1765322T3 (da) | Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser | |
| CY2014007I2 (el) | Μεθοδοι για την αγωγη διαταραχων ή παθησεων που συσχετιζονται με υπερλιπιδαιμια και υπερχοληστερολαιμια ενω ελαχιστοποιουνται οι παρενεργειες | |
| DK1593387T3 (da) | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser | |
| EP2347767A3 (en) | Immune regulation based on the targeting of early activation molecules | |
| CY1111467T1 (el) | Μορια ανθρωπινου αντισωματος για την il-13 | |
| ATE498010T1 (de) | Natürliche igm-antikörper und inhibitoren davon | |
| WO2006048781A3 (en) | IgE-RETARGETING, FUNCTION-ALTERING MOLECULES (ERFAM) FOR TREATMENT OF ALLERGIC DISEASES | |
| TNSN08175A1 (en) | Human antibodies against il-13 and therapeutic uses | |
| TH101957A (th) | แอนตี้บอดี้ต่อ il-13 ของมนุษย์และการใช้ทางอายุรเวช | |
| Kang et al. | A Study on Psychological Effect of Natural Element in Rest Space of Office | |
| TH98075B (th) | แอนตี้-tslp แอนตี้บอดี้ | |
| Roelants | Effect of vibration training on muscle strength, muscle performance and velocity-related mechanical muscle characteristics | |
| Yong | Effects of protein glutaminase treatments on structure and functional properties of cereal proteins | |
| UA97232C2 (ru) | Изолированное антитело, которое связывает моноцитный хемоатрактантный белок 1 (мср-1) человека | |
| IL206133A0 (en) | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |